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Abstract 
Purpose: To report a case of proliferative diabetic retinopathy (PDR) showing transient 
macular edema (ME) and deteriorated retinal function after intravitreal bevacizumab 
injection (IVB).  
Methods and Results: A 53-year-old man received IVB (1.25 mg/0.05 ml) in both eyes for 
the treatment of PDR. There was no treatment-related complication. However, he 
complained of photopsia in both eyes 6 h after the injection. Slit-lamp examination 
revealed mild cellular infiltrations (1+) in the anterior chamber in both eyes. Optical 
coherence tomography showed ME formation in the left eye. Both full-field and 
multifocal electroretinography (ERG) revealed the deterioration of all parameters in both 
eyes compared with pretreatment. The inflammation in the anterior segment and ME 
disappeared 1 day after the injection. ERG parameters were improved 9 days after the 
injection, except for the N1 and P1 amplitude of multifocal ERG in the left eye.  
Conclusion: We propose that patients who undergo IVB should be carefully informed 
and followed up for possible complications including temporal ME formation and retinal 
function deterioration. 
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A number of reports described the benefit of intravitreal bevacizumab (Avastin; 
Genentech, Inc., South San Francisco, Calif., USA) injection (IVB) for proliferative 
diabetic retinopathy (PDR) [1–3]. Excessive fibrosis of fibrovascular membrane (FVM) 
and tractional retinal detachment after IVB are reported to date [4–6]. In this report, we 
present a case of PDR showing transient macular edema (ME) and deteriorated retinal 
function after IVB. 
Case Report 
A 53-year-old man consulted our hospital for the treatment of PDR in both eyes. At the first visit, 
the best corrected visual acuity measured by Landolt ring chart was 1.0 in both eyes. No remarkable 
finding was observed in the anterior segment. Fundoscopic examination revealed normal macular 
appearance and apparent FVM on the disc and elsewhere. Scattered chorioretinal scars from retinal 
photocoagulation performed more than 3 months before were also found. Fluorescein angiography 
showed remarkable leakages of dye from the FVM (fig. 1a). However, the optical coherence 
tomography (OCT) findings showed normal macular appearances (fig. 2). To reduce the activity of 
FVM, we performed off-label IVB (1.25 mg/0.05 ml) in both eyes with the patient’s written informed 
consent, the approval of the institutional review board of Kobe University of Medicine and the tenets of 
the Declaration of Helsinki. Although no complication occurred during the surgical procedures, the 
patient complained of photopsia in both eyes 6 h after the injection. Slit-lamp examination revealed 
mild cellular infiltrations (1+) in the anterior chamber in both eyes. Although the fundoscopic findings 
in both eyes did not reveal any retinal change, the OCT showed ME formation in the left eye (fig. 2). 
Both full-field and multifocal electroretinography (ERG) revealed the deterioration of all parameters in 
both eyes compared with pretreatment (fig. 3). The next day, the inflammation in the anterior segment 
and ME disappeared (fig. 2), and after 9 days, the patient’s complaint had totally disappeared. Best 
corrected visual acuity was maintained at 1.0 in both eyes during the event. Fluorescein angiography 
revealed leakage reduction (fig. 1b). Moreover, 9 days after the injection, ERG parameters were 
improved, except for the N1 and P1 amplitude of multifocal ERG in the left eye (fig. 3). 
Discussion 
Although Fung et al. [7] published the incidence of ocular inflammation related to 
IVB, they did not evaluate the structural change of the retina after the injection. To our 
knowledge, this is the first report describing ocular inflammation accompanied by ME 
shortly after IVB. It is known that ME usually results from accelerated breakdown of the 
blood-retinal barrier due to PDR. However, in our case, apparent ME occurred quite 
rapidly after IVB, which suggests that ME was induced by the surgical procedure or by 
bevacizumab itself. Forooghian et al. [8] reported aqueous vascular endothelial growth 
factor (VEGF) downregulation and the upregulation of inflammatory cytokines (TGF-β2 
and IL-8) after IVB. They discussed that acute elevation of these inflammatory cytokines 
may mediate a rapid contraction of FVM, thereby causing tractional retinal detachment. 
Since there is no report demonstrating such a rapid appearance of ME after IVB, we 
suggest that the acute alteration of the intraocular cytokine concentration might have had 
a predominant role in inducing inflammatory ME in the present case. 
The ERG findings showed a functional deterioration after IVB. Changes of all ERG 
parameters were determined after only 6 h following IVB, corresponding to the slit-lamp 
and OCT findings, but the recovery of the ERG parameters was delayed compared to the 
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subclinical dysfunction of the retina lasts relatively longer than morphological changes. 
Peters et al. [9] showed the reduction of choriocapillaris endothelial cell fenestrations 
after IVB, and Heiduschka et al. [10] showed the penetration of bevacizumab through the 
retina and diminished immunoreactivity of VEGF in the retina 14 days after IVB. They 
suggested that these ultrastructural changes may lead to functional and morphologic 
damage of retinal pigment epitheliums and photoreceptors. We considered that the 
VEGF withdrawal after IVB suppressed the physiological neurotrophic effect of VEGF 
[11], and caused temporal retinal dysfunction accompanied by the abnormal ERG 
parameters. 
In summary, we propose that patients who undergo IVB should be carefully informed 








Fig. 1. Late-phase fluorescein angiography findings. a Leakages from neovascularizations on the disc 
and elsewhere were seen before IVB in both eyes. b Leakages from neovascularizations were reduced 9 
days after the injection. 
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Fig. 2. Upper panel: transition of retinal thickness and total macular volume in OCT. Lower panel: 
transition of the horizontal line and the color map image of retinal thickness in OCT. Before the 
injection, OCT findings showed normal macular appearances in both eyes. The retinal thickness and 
total macular volume in the left eye were increased 6 h after the injection. OCT findings in the left eye 
improved after 1 day and were kept normal after that. OCT findings in the right eye were kept normal 
during the follow-up period. 
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Fig. 3. Transition of ERG parameters. Upper panel: transition of full-field bright-flash ERG. Lower 
panel: transition of multifocal ERG at 3 central rings of 103 hexagon analysis. In both methods, all ERG 
parameters worsened 6 h after the injection and improved with time, except for the N1 and P1 
amplitudes of the left eye. 
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